Change search
ReferencesLink to record
Permanent link

Direct link
Amyloid-beta-directed immunotherapy for Alzheimer's disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Geriatrics.
2014 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 275, no 3, 284-295 p.Article in journal (Refereed) Published
Abstract [en]

Current treatment options for Alzheimer's disease (AD) are limited to medications that reduce dementia symptoms. Given the rapidly ageing populations in most areas of the world, new therapeutic interventions for AD are urgently needed. In recent years, a number of drug candidates targeting the amyloid-ss (A ss) peptide have advanced into clinical trials; however, most have failed because of safety issues or lack of efficacy. The A ss peptide is central to the pathogenesis, and immunotherapy against A ss has attracted considerable interest. It offers the possibility to reach the target with highly specific drugs. Active immunization and passive immunization have been the most widely studied approaches to immunotherapy of AD. A favourable aspect of active immunization is the capacity for a small number of vaccinations to generate a prolonged antibody response. A potential disadvantage is the variability in the antibody response across patients. The potential advantages of passive immunotherapy include the reproducible delivery of a known amount of therapeutic antibodies to the patient and rapid clearance of those antibodies if side effects develop. A disadvantage is the requirement for repeated infusions of antibodies over time. After more than a decade of research, anti-amyloid immunotherapy remains one of the most promising emerging strategies for developing disease-modifying treatments for AD. In this review, we examine the presently ongoing A ss-directed immunotherapies that have passed clinical development Phase IIa.

Place, publisher, year, edition, pages
2014. Vol. 275, no 3, 284-295 p.
Keyword [en]
Alzheimer's disease, amyloid-beta, clinical trials, immunotherapy
National Category
Geriatrics Medical and Health Sciences
URN: urn:nbn:se:uu:diva-227917DOI: 10.1111/joim.12168ISI: 000332446200006OAI: diva2:731553
Available from: 2014-07-01 Created: 2014-07-01 Last updated: 2014-07-01Bibliographically approved

Open Access in DiVA

fulltext(457 kB)67 downloads
File information
File name FULLTEXT01.pdfFile size 457 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Lannfelt, Lars
By organisation
In the same journal
Journal of Internal Medicine
GeriatricsMedical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 67 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 316 hits
ReferencesLink to record
Permanent link

Direct link